Dexamethasone and Ivacaftor interaction

Dexamethasone and Ivacaftor: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Dexamethasone (Hemady) label · effective 2026-01-09

Major

• Avoid concomitant use of strong CYP3A4 inhibitors or inducers.

Drug interactionsby drug classView label on DailyMed
Major

Avoid coadministration of strong CYP3A4 inhibitors or consider alternative medication that are not strong CYP3A4 inhibitors.

Drug interactionsby drug classView label on DailyMed
Major

If concomitant use of strong CYP3A4 inhibitors cannot be avoided, closely monitor for adverse drug reactions.

Drug interactionsby drug classView label on DailyMed
Moderate

( ‎7.2 ) 7.1 Effect of Other Drugs on HEMADY Strong CYP3A4 inhibitors Coadministration of strong and moderate CYP3A4 inhibitors increased dexamethasone exposure [see Clinical Pharmacology (‎ 12.3 )] , which may increase the risk of adverse reactions [see Warnings and Precautions (‎ 5 ) and Adverse Reactions (‎ 6 )] .

Drug interactionsby drug classView label on DailyMed

From the Ivacaftor (Kalydeco) label · effective 2026-03-23

Moderate

Concomitant Use with CYP3A Inducers Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Although other risk factors were present in some cases (such as corticosteroid use and/or exposure to radiation), a possible risk attributable to KALYDECO cannot be excluded.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Inducers of CYP3A Co-administration with rifampin, a strong CYP3A inducer, significantly decreased ivacaftor exposure (AUC) by approximately 9-fold.

Drug interactionsby drug classView label on DailyMed
Minor

Use with CYP3A inducers: Concomitant use with strong CYP3A inducers (e.g., rifampin, St.

Warnings and precautionsby drug classView label on DailyMed
Minor

Therefore, co-administration of KALYDECO with strong CYP3A inducers (e.g., rifampin, St.

Warnings and precautionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.